Perceptive Advisors, a major life sciences investment firm, significantly increased its stake in Tango Therapeutics (TNGX) during the second quarter of 2026. According to its quarterly 13F filing, the firm's position grew from 808.15K shares to 3.38M shares, a jump of over 317%. The value of Perceptive's holding in the precision oncology company increased from $16.91 million to $105.57 million. This disclosure reflects the firm's holdings as of June 30, 2026, and the trades occurred over the preceding quarter.
This increased investment came during a pivotal quarter for Tango Therapeutics, which announced promising initial Phase 1/2 data for its lead drug candidate, vopimetostat, in combination with daraxonrasib. The combination therapy showed a 92% objective response rate in certain pancreatic cancer patients. For the quarter ending June 30, 2026, Tango reported it held $1.0 billion in cash, cash equivalents, and marketable securities, positioning it to advance its clinical programs.